LBT Innovations Bags Up to AU$4.1 Million Contract with AstraZeneca; Shares Climb 33%
LBT Innovations (ASX:LBT) signed an agreement to sell five Automated Plate Assessment System (APAS) Independence instruments to AstraZeneca and provide maintenance and support services over seven years in a deal valued at AU$3.4 million to AU$4.1 million, according to a Wednesday filing with the Australian bourse.
The APAS instruments use artificial intelligence and machine learning software to automate the imaging, analysis, and interpretation of microbiology culture plates. They will be installed within the next six months, with a potential for additional orders, the filing said.
The medical technology company's shares climbed over 33% in recent trade.
Price (AUD): $0.02, Change: $+0.01, Percent Change: +33.33%
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。